Management of the thrombotic lesion

Percutaneous coronary intervention Microchapters

Home

Patient Information

Overview

Risk Stratification and Benefits of PCI

Preparation of the Patient for PCI

Equipment Used During PCI

Pharmacotherapy to Support PCI

Vascular Closure Devices

Recommendations for Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT

Post-PCI Management

Risk Reduction After PCI

Post-PCI follow up

Hybrid coronary revascularization

PCI approaches

PCI Complications

Factors Associated with Complications

Vessel Perforation

Dissection

Distal Embolization

No-reflow

Coronary Vasospasm

Abrupt Closure

Access Site Complications

Peri-procedure Bleeding

Restenosis

Renal Failure

Thrombocytopenia

Late Acquired Stent Malapposition

Loss of Side Branch

Multiple Complications

PCI in Specific Patients

Cardiogenic Shock

Left Main Coronary Artery Disease

Refractory Ventricular Arrhythmia

Severely Depressed Ventricular Function

Sole Remaining Conduit

Unprotected Left Main Patient

Adjuncts for High Risk PCI

PCI in Specific Lesion Types

Classification of the Lesion

The Calcified Lesion

The Ostial Lesion

The Angulated or Tortuous Lesion

The Bifurcation Lesion

The Long Lesion

The Bridge Lesion

Vasospasm

The Chronic Total Occlusion

The Left Internal Mammary Artery

Multivessel Disease

Distal Anastomotic Lesions

Left Main Intervention

The Thrombotic Lesion

Management of the thrombotic lesion On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Management of the thrombotic lesion

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Management of the thrombotic lesion

CDC on Management of the thrombotic lesion

Management of the thrombotic lesion in the news

Blogs on Management of the thrombotic lesion

Directions to Hospitals Treating Percutaneous coronary intervention

Risk calculators and risk factors for Management of the thrombotic lesion

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Brian C. Bigelow, M.D.

## Overview[edit | edit source]

The presence of angiographically apparent thrombus is associated with poorer outcomes in patients undergoing PCI. Thrombus often embolizes distally and causes no reflow and associated myonecrosis. There are two broad strategies to reduce thrombus burden: mechanical strategies and pharmacologic strategies.

## Management of The Thrombotic Lesion[edit | edit source]

### Differentiating Thrombus from Other Angiographic Abnormalities[edit | edit source]

* Coronary spasm can also lead to a focal narrowing of the lumen and should be treated with vasodilators
* A dissection can cause a hazy appearance to the lumen and should be treated with intracoronary stenting

### Goals of Treatment[edit | edit source]

Goals in the management of the thrombotic lesion include:

* Restoration of normal antegrade flow in the epicardial artery (TIMI Grade 3 Flow)
* Maintenance of normal perfusion in the downstream capillary bed or microvasculature (TIMI Myocardial Perfusion Grade 3)
* Resolution of thrombus burden
* Avoid distal embolization with abrupt cutoff of distal branches and side branches
* Avoid /reduce thrombotic major adverse cardiac events (MACE) which includes death, MI, recurrent ischemia, urgent target vessel revascularization (TVR).
* In the setting of ST segment elevation MI, the goal is to achieve greater than 70% ST segment resolution.

### Step-By-Step Strategy in the Management of the Thrombotic Lesion[edit | edit source]

* The first strategy is to prevent the occurrence of thrombus through the use of upstream antiplatelet and antithrombotic pharmacotherapies including aspirin, thienopyridines, and glycoprotein 2b3a inhibition.
* The second strategy is to mechanically aspirate thrombus.
* The third strategy is to direct stent the lesion without pre-dilation to minimize distal embolization.
* The fourth strategy is to utilize intracoronary fibrinolytic therapy to dissolve clot that is refractory to other forms of treatment and dissolve clot inside branches that may be accessible to mechanical devices.
* Alternate / additional strategies include the use of distal protection and saphenous vein grafts to minimize distal embolization.

### Pharmacologic Therapy[edit | edit source]

#### Antiplatelet Therapy[edit | edit source]

* The incidence of thrombus on the coronary angiogram can be reduced by and complications of the PCI procedure can be reduced by upstream pharmacologic therapy with antiplatelet therapy including aspirin, platelet glycoprotein IIb/IIIa receptor (GP IIb/IIIa) antagonists in patients who are troponin positive (abciximab, eptifibatide, tirofiban), and ADP receptor/P2Y12 inhibitors (plavix, ticagrelor, prasugrel)
* Aspirin is a conventional therapy that reduces ischemic complications after PCI.
* Glycoprotein IIb/IIIa antagonists are used adjunctively to treat and prevent thrombus formation and decreases ischemic complications post-PCI in patients with angiographic evidence of or suspected thrombus. In patients with STEMI undergoing primary PCI, glycoprotein IIb/IIIa antagonists have been shown to reduce mortality in meta-analyses. There is an ongoing debate as to the optimal timing of their administration (upstream vs in-lab administration).

#### Antithrombin Therapy[edit | edit source]

* Antithrombin Therapy: Ufractionated heparin (UFH), low molecular weight heparin (LMWH). Fondaparinux is not recommended in primary PCI.
* UFH is a conventionally used thrombin inhibitor that prevents arterial thrombus formation at the site of a vessel wall injury, on catheters, and on equipment during PCI.
* LMWH: ExTRACT-TIMI 25[1] demonstrated that there were improved clinical outcomes with LMWH in patients with STEMI undergoing fibrinolysis and subsequent PCI.
* Direct thrombin inhibitors (DTI): Hirudin, bivalirudin, argatroban may be used as an alternative to heparin and GP IIb/IIIa. The optimal strategy is to pre-load with clopidogrel if a DTI is used, which is the drug of choice in patients with a history of heparin-induced thrombocytopenia.

#### Thrombolytic Therapy[edit | edit source]

* Thrombolytic Therapy: Urokinase (UK), tissue plasminogen activator (tPA) for STEMI when other pharmacologic and mechanical treatments are not successful. Caution: intracoronary administration of fibrinolytic agents is an "off label" the use of these agents (this mode of administration is not been approved by the FDA, but fibrinolytic agents are an FDA approved drug). The total dose of tPA is 20 mg which is approximately the 1/5 of that generally used for systemic fibrinolysis. tPA can it be administered 2 mg at a time to evaluate its efficacy.

### Mechanical Therapy[edit | edit source]

#### Thrombus Aspiration[edit | edit source]

* Thrombus aspiration can be achieved with the Export, Pronto, and other devices
* Thrombus aspiration is the preferred treatment and has been associated with improved myocardial perfusion and mortality.
* Care should be exercised in very proximal lesions in the LAD and the circumflex, as the clot may embolize into the other artery.
* After aspiration, direct stenting is associated with improved rates of recurrent MI in meta-analyses, improved myocardial perfusion, and improved ST segment resolution. Stenting reduces the risk of abrupt closure.

#### Direct Stenting[edit | edit source]

* Direct placement of the stent without pre-dilation by a balloon has been associated with a reduction in myonecrosis in meta-analyses.

#### Distal Protection[edit | edit source]

* Distal Protection can be achieved with the following devices (Percusurge guardwire, Triactive, Spider wire, Proxis), particularly in saphenous vein grafts
* Occlusive (Percusurge guardwire, Triactive) and filter (Filterwire) methods may improve safety and efficacy of PCI in patients with thrombotic lesions in SVG; SAFER study of Percusurge device demonstrated lower rate of death/MI
* Distal embolic protection has not shown to be efficacious in the setting of STEMI in native coronary arteries with either Percusurge (EMERALD trial)[2] or Filterwire (PROMISE trial).[3]

#### Rheolytic Thrombectomy[edit | edit source]

* Rheolytic thrombectomy with Possis Angiojet was not found to have any benefit in the setting of STEMI in native coronary arteries in the AIMI trial. Infarct sizes were larger and mortality was higher.

#### Less Frequently Used Modalities[edit | edit source]

* Directional Atherectomy
* Transluminal Extraction Catheter (TEC)

### Management of No Reflow[edit | edit source]

Distal embolization of thrombus often occurs, and you should be prepared to treat the patient for potential spasm or no-reflow with a calcium channel blocker, adenosine (100 mcg IC) or nitroprusside (100 mcg IC).

## References[edit | edit source]

1. ↑ White HD, Braunwald E, Murphy SA; et al. (2007). "Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25". Eur. Heart J. 28 (9): 1066–71. doi:10.1093/eurheartj/ehm081. PMID 17456482. Unknown parameter `|month=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
2. ↑ Nikolsky E, Stone GW, Lee E; et al. (2009). "Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial". EuroIntervention. 5 (4): 417–24. PMID 19755327. Unknown parameter `|month=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
3. ↑ Gick M, Jander N, Bestehorn HP; et al. (2005). "Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation". Circulation. 112 (10): 1462–9. doi:10.1161/CIRCULATIONAHA.105.545178. PMID 16129793. Unknown parameter `|month=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)

Template:WikiDoc Sources